8-K: Cerus Corporation Raises Full-Year Revenue Guidance After Strong Second Quarter

Cerus Corporation announced a 20% increase in first-half product revenue and raised its full-year 2024 product revenue guidance range to $175-178 million.

Summary

• Cerus Corporation reported its financial results for the second quarter of 2024, showing a 20% increase in product revenue for the first half of the year compared to the same period last year.
• The company's total revenue for the second quarter was $50.5 million, a 6% increase year-over-year, while product revenue alone grew by 16% to $45.1 million.
• Government contract revenue decreased by 39% in the second quarter to $5.4 million due to the completion of a clinical trial.
• The company narrowed its GAAP net loss to $5.8 million for the quarter and generated a non-GAAP adjusted EBITDA of $0.8 million.
• Cerus generated positive operating cash flows for the second consecutive quarter, bringing the year-to-date total to $2.4 million.
• The company increased its full-year 2024 product revenue guidance from $172-175 million to $175-178 million, which includes $8-10 million for INTERCEPT Fibrinogen Complex (IFC).
• Cerus is aiming for adjusted EBITDA breakeven for the full year 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the increased revenue guidance, improved profitability metrics, and strong growth in key business areas. While there are risks, the overall tone is optimistic and suggests a positive outlook for the company.

Positives

• The company experienced strong growth in its platelet business, particularly in North America.
• The adoption of INTERCEPT platelets by Canadian Blood Services is a significant achievement.
• The company is making progress towards profitability with improved EBITDA and positive cash flow.
• The increase in full-year revenue guidance indicates confidence in future performance.
• The IFC business is showing signs of acceleration with increasing recognition of its benefits.
• Operating expenses decreased by 19% year-over-year due to restructuring and completion of key initiatives.

Negatives

• Government contract revenue decreased significantly by 39% in the second quarter.
• The company still reported a net loss of $5.8 million for the second quarter, although it is an improvement from the previous year.
• The company has a significant amount of debt with $65 million outstanding on its term loan and $18.8 million drawn on its revolving credit facility.

Risks

• The company faces risks associated with the commercialization and market acceptance of the INTERCEPT Blood System.
• Macroeconomic developments, including military conflicts and the COVID-19 pandemic, could negatively impact the business.
• There are risks related to the regulatory process and the ability to obtain necessary approvals for new products.
• The company relies on third parties for manufacturing and distribution, which could pose supply chain risks.
• The company needs to access additional funds under its credit facility and may require additional funding in the future.
• There are risks related to product safety and the effectiveness of the INTERCEPT Blood System.

Future Outlook

The company expects full-year 2024 product revenue to be in the range of $175 million to $178 million and aims to achieve adjusted EBITDA breakeven for the full year. They also expect continued improvements to GAAP net loss for the full year 2024.

Management Comments

• William Obi Greenman, Cerus president and chief executive officer, stated that they are very pleased to post another strong quarter to continue their growth trajectory in 2024.
• Greenman also noted that North American sales in their platelet business led the way, including both organic U.S. sales growth and 100% adoption by Canadian Blood Services.
• Greenman mentioned that the IFC business is accelerating with respect to the increasing recognition of its pivotal early role in the care of bleeding patients and its improved operational ease of use for hospital transfusion services.
• Greenman also stated that they are extremely pleased with their execution to date on key financial measures, namely adjusted EBITDA and operating cash flows.

Industry Context

This announcement reflects a positive trend for Cerus in the blood product industry, particularly with the increasing adoption of pathogen reduction technologies. The company's focus on expanding its IFC business aligns with the growing need for effective treatments for bleeding patients. The 100% adoption by Canadian Blood Services is a significant win for the company and a positive sign for the industry.

Comparison to Industry Standards

• Cerus's 20% growth in first-half product revenue is strong compared to the overall growth rate of the blood products market, which is typically in the single-digit percentages.
• The company's focus on pathogen reduction technology aligns with the industry's increasing emphasis on blood safety, which is a key differentiator for Cerus.
• Companies like Haemonetics and Terumo BCT are also involved in blood component processing, but Cerus's INTERCEPT system is unique in its pathogen reduction capabilities.
• The achievement of 100% adoption by Canadian Blood Services is a significant milestone, demonstrating the effectiveness and acceptance of the INTERCEPT system in a major market.
• The company's move towards EBITDA breakeven is a positive sign, as many biotech companies struggle with profitability in their early stages.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and improved financial performance.
• Employees may feel more secure with the company's improved financial stability and growth prospects.
• Customers, including blood centers and hospitals, will benefit from the continued availability of safe and effective blood products.
• Suppliers may see increased demand for their products as Cerus expands its operations.
• Creditors may view the company as a lower risk due to its improved cash flow and profitability.

Next Steps

• The company will continue to focus on achieving non-GAAP adjusted EBITDA breakeven for the full-year 2024.
• Cerus will continue its efforts to improve on key financial metrics during the back half of 2024.
• The company will host a conference call to discuss the financial results and provide a general business overview and outlook.

Key Dates

Keywords

Cerus Corporation, INTERCEPT Blood System, Product Revenue, EBITDA, Pathogen Reduction, Platelets, Plasma, Fibrinogen Complex, Blood Supply, Financial Results